The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is the third most common cancer and a common cause of cancer‐related mortality globally. In spite of the improvements in the early diagnosis of CRC, approximately one‐third of patients develop metastasis and then have a very poor survival rate. The mesenchymal–epithelial transition factor (c‐MET) is a tyrosine kinase cell surface receptor activated by hepatocyte growth factor (HGF). Activation of c‐MET/HGF signaling pathway regulates a variety of biological processes including cell motility, cell proliferation, angiogenesis, the epithelial‐to‐mesenchymal transition, and the development and progression of cancer cells. Recent studies have suggested that the c‐MET/HGF signaling pathway is involved in the carcinogenesis of CRC. In this review, we summarize the main findings of recent studies investigating the role of c‐MET/HGF signaling pathway in CRC and the potential of the c‐MET/HGF signaling pathways in the diagnosis and treatment of CRC. © 2019 IUBMB Life, 2019
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · cited 1×
“It has been seen that there is a correlation between KRAS genemutation and resistance to anti-EGFR receptor (79).”
BackgroundFrampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796 · cited 1×
“Deletion of the juxtamembrane domain is responsible for this downregulation delay (30).”
BackgroundThe role of TGF-β/SMAD4 signaling in cancer
Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631 · cited 1×
“reported to be involved during transition from normal colorectal epithelium to cancerous and also in CRC progression, including the toll-like receptor signaling pathway (7), the Wnt/β-catenin signaling pathway signaling pathway (8), the death receptor signaling pathway (9), the rat sarcoma viral oncogene homolog (RAS)…”
BackgroundVan Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2752 · Cited by 110
Inno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagalà, C., Cassano, A., Larocca, L. M., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.028 · Cited by 83 · cited 1×
“, 2011 (70) 73 metastatic CRC IHC c-MET overexpression significantly associated with poor OS and PFS”
BackgroundEng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72 · cited 1×
“…previously treated metastatic CRC Tivantinib and CPT-11 plus C 360 mg of RPTD twice daily was well tolerated with preliminary antitumor activity Eng et al., 2016 (47) 122 locally advanced or metastatic CRC Tivantinib and CETIRI No improvement in OS and PFS by adding tivantinib to CETIRI Pineda…”
Background
Cited by
Recent advances in targeted drug delivery systems for resistant colorectal cancer
Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65
Deng, L., Jiang, N., Zeng, J., Wang, Y., & Cui, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.733270 · Cited by 51
Ramezani, S., Parkhideh, A., Bhattacharya, P. K., Farach-Carson, M. C., & Harrington, D. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657701 · Cited by 11
Metadata
- Authors
- Parizadeh, S. M., Jafarzadeh‐Esfehani, R., Fazilat‐Panah, D., Hassanian, S. M., Shahidsales, S., Khazaei, M., Parizadeh, S. M. R., Ghayour‐Mobarhan, M., Ferns, G. A., & Avan, A.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2019-05-22
- Volume
- 71
- Issue
- 7
- Pages
- 802-811
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W2944846069
- Cited by
- 54
- References
- 6
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer. https://app.cochat.ai/papers/10.1002/iub.2063
- The paper
- Parizadeh, S. M., Jafarzadeh‐Esfehani, R., Fazilat‐Panah, D., Hassanian, S. M., Shahidsales, S., Khazaei, M., Parizadeh, S. M. R., Ghayour‐Mobarhan, M., Ferns, G. A., & Avan, A. (2019). The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer. IUBMB Life. https://doi.org/10.1002/iub.2063
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.